COLL — COLLEGIUM PHARMACEUTICAL, INC
Price · 2024-08-26 → 2026-08-21
499 daily closes shownAnonymous view is capped at two years of history. A free account extends it to five, and Pro opens the whole archive back to 2016-01-04.
Performance
Technicals
Others in Healthcare
Measured signals that fired on COLL
| date | signal | measured base rate |
|---|---|---|
| 2026-08-06 | Bollinger bandwidth breaks out of its own compression structure | -0.63% over 21 days · t = -2.80 · n = 7,196 statistically distinguishable from its control group |
| 2026-08-06 | Fair value gap, bearish structure | -0.45% over 21 days · t = -3.29 · n = 108,591 statistically distinguishable from its control group |
| 2026-07-16 | Fair value gap, bullish structure | -0.67% over 21 days · t = -6.43 · n = 111,973 statistically distinguishable from its control group |
| 2026-06-05 | Fair value gap, bullish structure | -0.67% over 21 days · t = -6.43 · n = 111,973 statistically distinguishable from its control group |
| 2026-05-18 | Cluster sale: three or more insiders insider | -0.36% over 21 days · t = -3.35 · n = 21,529 statistically distinguishable from its control group |
| 2026-05-12 | Fair value gap, bearish structure | -0.45% over 21 days · t = -3.29 · n = 108,591 statistically distinguishable from its control group |
Excess return against a matched control group, on a point-in-time universe that includes delisted companies. Most families do not survive that. How the measurement works →
Insider transactions (Form 4)
| date | insider | what | shares | price | value |
|---|---|---|---|---|---|
| 2026-06-08 | SANTINI GINO Director | Option exercise | 8.7K | 16.49 | 143.5K |
| 2026-05-18 | Freund John Gordon Director | Open-market sale | 20 | 34.05 | 681 |
| 2026-05-15 | Freund John Gordon Director | Option exercise | 8.7K | 16.49 | 143.5K |
| 2026-05-15 | Freund John Gordon Director | Open-market sale | 4.1K | 34.54 | 142.5K |
| 2026-05-14 | Freund John Gordon Director | Grant or award | 8.7K | 0.00 | 0 |
| 2026-05-14 | SANTINI GINO Director | Grant or award | 8.7K | 0.00 | 0 |
| 2026-05-14 | Lurker Nancy Director | Grant or award | 8.7K | 0.00 | 0 |
| 2026-05-14 | Balice-Gordon Rita J. Director | Grant or award | 8.7K | 0.00 | 0 |
| 2026-05-14 | Paya Carlos V Director | Grant or award | 8.7K | 0.00 | 0 |
| 2026-05-14 | BOHLIN GAREN G Director | Grant or award | 8.7K | 0.00 | 0 |
Open-market purchases (code P) are the informative ones. Grants, option exercises and tax withholding are compensation mechanics, not decisions. How to read a Form 4 →
Largest institutional holders
| manager | value | shares |
|---|---|---|
| BlackRock, Inc. | 169.8M | 5.1M |
| JANUS HENDERSON GROUP PLC | 60.4M | 1.8M |
| Invesco Ltd. | 52.6M | 1.6M |
| FULLER & THALER ASSET MANAGEMENT, INC. | 49.6M | 1.5M |
| RENAISSANCE TECHNOLOGIES LLC | 48.6M | 1.5M |
| STATE STREET CORP | 47.1M | 1.4M |
| EVENTIDE ASSET MANAGEMENT, LLC | 47.1M | 1.4M |
| MASSACHUSETTS FINANCIAL SERVICES CO /MA/ | 45.2M | 1.4M |
| VANGUARD CAPITAL MANAGEMENT LLC | 44.1M | 1.3M |
| PRINCIPAL FINANCIAL GROUP INC | 42.8M | 1.3M |
13F positions as of 2026-03-31, filed up to 45 days after quarter end. Long-only US equity — shorts and derivatives never appear. What 13F does and does not show →
Short selling
This is off-exchange short volume, not short interest: it is flow, not position, and 40–50% is normal because market makers short to fill your buy. Why that number misleads →
Recent headlines
- Why is Collegium Pharmaceutical stock climbing today? · 2026-08-13
- Collegium Pharmaceutical stock jumps on $50M share buyback · 2026-08-13
- Collegium Pharmaceutical (COLL) Q2 2026 Earnings Call Transcript · 2026-08-13
- Collegium Pharmaceutical, Inc (COLL) filed form 8-K · 2026-08-13 · SEC EDGAR
Ask the AI about COLL
The assistant reads every block on this page — price history, filings, insider transactions, institutional positions, short volume, macro and the measured base rates — and says what it implies, quoting the number behind each claim and declaring what it does not have.
Everything on this page is live in the terminal.
Charts, filings, insider flow and the AI — open without an account.
Free plan for good. Pro is $69.99/mo, or $4.99 for a 7-day trial. See the plans →